EP1363660A2
Superior molecular vaccine based on self-replicating rna, suicidal dna or naked dna vector, that links antigen with polypeptide that promotes antigen presentation
Abstract
This record has no abstract on file.
Term
Term ended
Projected expiry passed 1 February 2022, 4.6 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| US9758551B2 | Cited by | United States of America | Applicant |
| US9701725B2 | Cited by | United States of America | Applicant |
8 members in 4 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 265334P | United States of America | – | |
| 26533401 | United States of America | P | |
| 0202598 | United States of America | W |
Members8
| Document | Office | Kind | |
|---|---|---|---|
| WO02061113A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU2002242016A1 | Australia | A1 | |
| WO02061113A3 | World Intellectual Property Organization (WIPO) | A3 | |
| EP1363660A2This record | European Patent Office (EPO) | A2 | |
| WO02061113A9 | World Intellectual Property Organization (WIPO) | A9 | |
| US2005277605A1 | United States of America | A1 | |
| EP1363660A4 | European Patent Office (EPO) | A4 | |
| US7557200B2 | United States of America | B2 |
12 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Application deemed to be withdrawnWithdrawn18D | 18D | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWNSTAA | STAA | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: EXAMINATION IS IN PROGRESSSTAA | STAA | |
| First examination report despatched17Q | 17Q | |
| Supplementary search report drawn up and despatchedA4 | A4 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Request for examination filed17P | 17P | |
| Designated contracting statesAK | AK | |
| Request for extension of the european patentAX | AX | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI |
Numbers
- Publication
- 1363660
- Application
- 27076181
Titles3
- German
- "ÜBERLEGENE MOLEKULARE VAKZINE AUF BASIS SELBSTREPLIZIERENDER RNA, SUIZID-DNA ODER NACKTEM DNA-VEKTOR, ZUR VERKNÜPFUNG VON ANTIGEN MIT POLYPEPTID ZUR FÖRDERUNG DER ANTIGENPRÄSENTATION"
- English
- SUPERIOR MOLECULAR VACCINE BASED ON SELF-REPLICATING RNA, SUICIDAL DNA OR NAKED DNA VECTOR, THAT LINKS ANTIGEN WITH POLYPEPTIDE THAT PROMOTES ANTIGEN PRESENTATION
- French
- VACCIN MOLECULAIRE SUPERIEUR A BASE D'ARN AUTOREPLICATIF, D'ADN SUICIDE OU DE VECTEUR D'ADN NU, QUI LIE UN ANTIGENE A UN POLYPEPTIDE QUI FAVORISE LA PRESENTATION DE L'ANTIGENE
Classification
- CPC, 14
- C07K14/005
- A61K35/13
- A61K2039/5256
- A61K2039/53
- C07K2319/40
- C07K2319/74
- C12N7/00
- C12N2710/20022
- C12N2770/36143
- C12N2830/008
- A61K40/19
- A61K40/24
- A61K40/11
- A61K40/4262
- IPC, 6
- A61K39 00
- A61K48 00
- C07H21 04
- C07K14 025
- C12N15 85
- C12N15 62
Designated states26
- Contracting states, 20
- Austria
- Belgium
- Switzerland
- Cyprus
- Germany
- Denmark
- Spain
- Finland
- France
- United Kingdom
- Greece
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Portugal
- Sweden
- Türkiye
- Extension states, 6
- Albania
- Lithuania
- Latvia
- North Macedonia
- Romania
- Slovenia